IGF-1 DES

IGF-1 DES is a 67-amino-acid form of insulin-like growth factor 1 that shows stronger growth effects than native IGF-1 in cells and some animals because it largely escapes IGF-binding proteins. No human trial proves muscle gain, a safe dose, or spot growth. IGF-1 DES is unapproved in the United States and banned in tested sport.

What is IGF-1 DES?

IGF-1 DES is des(1-3)IGF-1: natural 70-amino-acid IGF-1 with the first three residues, Gly-Pro-Glu, removed. The truncated form has been isolated from bovine colostrum, human brain, and porcine uterus; research copies are also made in laboratories.

The missing three residues matter more than the small size change suggests. The 1996 Ballard and Francis-era review found that des(1-3)IGF-I was generally about ten times as potent as native IGF-1 at stimulating hypertrophy and proliferation in cultured cells. That does not mean the IGF des peptide grips its receptor ten times harder. It means less of the peptide gets parked by binding proteins before reaching the receptor.

How does des(1-3)IGF-1 work?

Des(1-3)IGF-1 activates the IGF-1 receptor while binding many insulin-like growth factor-binding proteins (IGFBPs) weakly. IGFBPs normally act like storage clips: they carry IGF-1, limit how much is free, and shape where and when signaling occurs. Remove Gly-Pro-Glu, and that restraint changes.

The often-repeated “100-fold” line needs a label. In cultured rat bone cells, des-IGF-I was 100-fold less effective than native IGF-I at binding a partially purified mixture of IGF-binding proteins. That paper did not establish a universal 100-fold reduction specifically for IGFBP-3. The broader evidence supports much weaker IGFBP binding and roughly tenfold higher potency in many cell assays; collapsing those into one magic number is how research pages become sales copy.

What does the research show?

IGF-1 DES has in-vitro and animal evidence, but no human treatment trial. Cultured cells provide the clearest potency result. In growth-hormone-deficient mice, des(1-3)IGF-I increased several organ weights at doses where native IGF-I did less, although body-weight changes were not statistically significant (Tomas et al., 1990). In diabetic rats, IGF peptides increased muscle protein synthesis and improved nitrogen balance; des(1-3)IGF-I was at least as potent as full-length IGF-I.

Those studies establish biological activity, not a physique outcome. They did not enroll lifters, measure a lagging biceps after local injection, or test a market vial. Exact-title and intervention searches of ClinicalTrials.gov return no registered IGF-1 DES study. The honest grade is animal-only, none in humans. The proof is at an early rung, not a failed human program.

Does IGF-1 DES site injection cause spot growth?

IGF-1 DES site injection has no controlled evidence showing selective growth of the injected human muscle. The claim is usually built from two facts: DES escapes binding proteins, and IGF signaling can act locally. Neither fact proves that an intramuscular shot enlarges only the nearby muscle.

The animal studies used systemic administration or tissue models, not a bodybuilding-style left-versus-right muscle experiment. A pump, training session, measurement error, and other drugs can all look like “spot growth” without proving it. Local signaling is a plausible research question. A proven spot-growth method is a different claim, and the study needed to support it has not been done.

What is the IGF-1 DES half life?

The IGF-1 DES half life has not been established in humans, so the familiar 20-to-30-minute figure should not be treated as measured human pharmacokinetics. No opened primary source traced that number to a DES trial in people. Less binding does suggest different clearance from native IGF-1, but direction and duration depend on route, species, dose, and the binding proteins present.

DES is also distinct from IGF-1 LR3, an 83-amino-acid engineered analogue with a 13-residue extension and an arginine substitution. LR3 was designed for prolonged activity; DES is a 67-residue truncation studied for weak IGFBP binding. “IGF-1 DES vs LR3” is not simply strong versus stronger. It is two different molecules with no human muscle-building trial for either.

Is there a studied IGF-1 DES dosage?

No IGF-1 DES dosage has been established for people. Published DES experiments report doses for cells, rats, mice, pigs, or marmosets; converting any of those into a human injection protocol would be guesswork. Online microgram schedules are community practice, not clinical evidence.

That distinction also applies to route. No human study has compared subcutaneous with intramuscular use, timed dosing around training, or local with systemic administration. A dose table would look useful while answering a question science has not answered. For context on reading that gap, see the site’s evidence-grading guide.

Is IGF-1 DES safe? Side effects

IGF-1 DES has no human safety dataset, and its clearest credible risks come from IGF biology and animal work. IGF variants that bind poorly to IGFBPs lowered glucose more strongly than native IGF-I in pigs and marmosets (Tomas et al., 1997). The approved native IGF-1 medicine, mecasermin, carries warnings for severe hypoglycemia, tissue overgrowth, and malignant neoplasia (DailyMed).

Those label risks cannot be assigned a frequency for DES; the molecules and evidence bases differ. They do show why “short acting” does not mean harmless. Research-use vials add separate uncertainty around identity, concentration, sterility, and storage. There is no verified human adverse-event rate to print.

Is IGF-1 DES legal or FDA-approved in 2026?

IGF-1 DES is not FDA-approved for any human use as of July 16, 2026; material sold under that name is research-use-only, not an approved medicine or dietary supplement. Increlex is sometimes used to blur this point, but its active ingredient is mecasermin: native recombinant 70-amino-acid human IGF-1, approved for narrowly defined pediatric growth failure. DES is a different 67-amino-acid molecule.

For the practical meaning of that label, see what research use only means. Athletes have another clear line: the 2026 WADA list prohibits IGF-1 and its analogues under S2 at all times. DES also belongs in the growth-hormone peptide family, while MK-677 works upstream by prompting the body to release growth hormone and has actual human trials.

What is the bottom line on IGF-1 DES?

IGF-1 DES is an active research molecule with a clean mechanistic story and an unfinished human one. Deleting three amino acids reduces binding-protein restraint, which can make DES look roughly ten times more potent than native IGF-1 in cell systems. Animal results confirm that the signal can affect tissue growth and glucose.

The market adds claims the papers do not: a precise human half-life, a validated IGF-1 DES dosage, and reliable growth at an injection site. None has human trial support. “Shorter peptide that dodges binding proteins” is accurate; “proven spot-growth IGF” is not.